IGF1R and neoplasm: They show anti-tumor activity against various targets such as EGFR, vascular endothelial growth factor (VEGF), PD-1, CTLA-4, receptor activator of nuclear factor-kappa B ligand (RANKL), insulin-like growth factor 1 receptor (IGF-1R), human epidermal growth factor receptor (HER2), cMET, and AXL [92].